Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: UCB, LAVA Therapeutics and More
Recent executive moves in the industry include C-suite changes at Arcus Biosciences and UCB. Meanwhile, new directors were appointed at Arovella Therapeutics and LAVA Therapeutics.
Executives On The Move: Changes At Albireo Pharma, AbbVie And Lundbeck
Recent executive moves in the industry include C-suite changes at Albireo Pharma, Aptevo Therapeutics and AbbVie. Meanwhile, new directors were appointed at Amarin and Oculis Holding.
Executives On The Move: Avidity Biosciences, Exicure and More
Recent executive moves in the industry include C-suite changes at Avidity Biosciences and BioAtla. Meanwhile, new directors were appointed at Exicure and Alimera Sciences.
No Slowdown From Bayer On Business Development Front
“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
Viatris To Bring In Plenty Of Brand Knowledge With New CEO Smith
Only three months after joining Viatris’ board of directors, Scott Smith, famed for spearheading Celgene’s successful and lucrative Inflammation and Immunology division, has been announced as the company’s new CEO, beginning 1 April.
Executives On The Move: Sandoz, Clyra Medical Technologies, IRLAB Therapeutics and More
Recent executive moves in the industry include C-suite changes IRLAB Therapeutics and Mercy Bioanalytics. Meanwhile, new directors were appointed at Clyra Medical Technologies and Jasper Therapeutics, while Sandoz has a new chairman-designate.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
Business Development Remains Top Priority For Ipsen
CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.
Executives On The Move: Medexus Pharmaceuticals, Alliance Pharma and More
Recent executive moves in the industry include C-suite changes Alliance Pharma and Race Oncology. Meanwhile, new directors were appointed at Medexus Pharmaceuticals and Scancell Holdings.
For Some Biotechs, IRA Remains Intangible – For Now
Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.